Form 4: Haemonetics COO Frank Chan Reports Stock Transactions

Haemonetics Corporation EVP and COO Frank Chan reported the vesting of restricted stock units and the withholding of shares for tax obligations.

Summary

• Frank Chan, EVP and Chief Operating Officer of Haemonetics Corporation, engaged in two transactions on May 15, 2026.
• 546 shares were withheld by the company to satisfy tax obligations related to the vesting of restricted stock units (RSUs).
• 27,535 RSUs were granted to the reporting person under the 2019 Long-Term Incentive Compensation Plan.
• Following these transactions, the reporting person holds a total of 32,936 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive equity compensation.

Positives

• The transaction reflects the vesting of equity-based compensation, aligning executive interests with long-term shareholder value.

Negatives

• The withholding of 546 shares for tax purposes represents a minor reduction in potential direct ownership, though it is a standard administrative procedure.

Risks

• The value of the granted RSUs is subject to future market performance of Haemonetics common stock.

Future Outlook

The RSUs granted vest in three annual installments: 40% on the first anniversary, 40% on the second, and 20% on the third.

Management Comments

• Each RSU represents a contingent right to receive one share of the Issuer's common stock when vested.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive compensation and does not signal a change in corporate strategy or market outlook.

Comparison to Industry Standards

• The use of RSU grants with multi-year vesting schedules is standard practice for executive retention in the medical device and healthcare technology sectors.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the newly granted RSUs over the next three years.

Key Dates

Keywords

Haemonetics, HAE, Insider Trading, Form 4, Executive Compensation, Restricted Stock Units